Show simple item record

dc.contributor.authorNarayanan, Raja
dc.date.accessioned2020-12-24T10:57:35Z
dc.date.available2020-12-24T10:57:35Z
dc.date.issued2020-01-10
dc.identifier.urihttp://hdl.handle.net/11718/23363
dc.descriptionCounterfeit avastin in India: punish the criminals, not the patients by Dr. Raja Narayanan, Director and Network Head at L V Prasad Eye Instituteen_US
dc.description.abstractIn December, 2015, 15 cases of intraocular inflammation following injections of counterfeit bevacizumab occurred in Gujarat, India. CDSCO reacted by prohibiting the use of intraocular bevacizumab throughout the country. Intense negotiations between the VRSI and CDSCO resulted in the permission to use bevacizumab in accordance with new safety guidelines. These include an enhanced informed consent process, the stamping of the Kezzler code on all bevacizumab vials, a real-time digital verification process between the end user and Roche Pharmaceuticals, and mandatory destruction of empty drug vials. Counterfeit bevacizumab has caused outbreaks of sterile and infectious post injection endophthalmitis in at least 3 countries during the past 5 years and has entered the supply chain in other countries. Physicians and compounding pharmacists need to be aware that international counterfeiters have targeted bevacizumab.en_US
dc.publisherIndian Institute of Management Ahmedabaden_US
dc.subjectCounterfeit avastinen_US
dc.subjectCounterfeit bevacizumaben_US
dc.subjectCounterfeiten_US
dc.subjectPatient in Indiaen_US
dc.subjectCDSCOen_US
dc.subjectVRSIen_US
dc.titleCounterfeit avastin in India: punish the criminals, not the patientsen_US
dc.typeVideoen_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record